# Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease

> **NCT02162251** · — · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 3482 (actual)

## Conditions studied

- Alzheimer's Desease

## Interventions

- **DRUG:** Donepezil Hydrochloride

## Key facts

- **NCT ID:** NCT02162251
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-01
- **Primary completion:** 2015-05-01
- **Final completion:** 2016-04-15
- **Target enrollment:** 3482 (ACTUAL)
- **Last updated:** 2018-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02162251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02162251, "Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02162251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*